stockrowGyre Therapeutics, Inc.
GYRE- Revenue
- +7.75%
- EPS
- −200.0%
- Free cash flow
- −129.9%
Quarter to September 2026, against a year earlier
Follow GYRE
Alert me
Gyre Therapeutics, Inc. (GYRE) Return on invested capital
Gyre Therapeutics, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −8.51%, down 16.5 percentage points from fiscal 2025 (7.99%). Over the past ten years it has ranged from −93.5% (fiscal 2023) to 14.1% (fiscal 2024); the current reading is higher than 82% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 7.99% | (6.09) |
| FY2024 | 14.1% | 107.53 |
| FY2023 | −93.5% | (105.68) |
| FY2022 | 12.2% | 12.23 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | 0.00 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| DMAC DiaMedica Therapeutics, Inc. compare | 0.00% |
| RGNX REGENXBIO Inc. compare | 0.00% |
| CBIO Crescent Biopharma, Inc. compare | 0.00% |
| VALN Valneva SE Sponsored ADR compare | 0.00% |
| INDP Indaptus Therapeutics, Inc. compare | 0.00% |
| NGNE Neurogene Inc. compare | 0.00% |
| GYRE Gyre Therapeutics, Inc. | −8.51% |
| CAPR Capricor Therapeutics, Inc. compare | −1,019.7% |
| ETRA Electra Therapeutics Inc. compare | — |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)